Compare Barclays PLC (BCS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barclays PLC vs GeneDx Holdings Corp — how do they compare? Barclays PLC trades at $28.1 (market cap $93.87B), while GeneDx Holdings Corp trades at $81.89 (market cap $2.44B). The key difference: Barclays PLC is far larger — about 38.5× GeneDx Holdings Corp's market cap, and Barclays PLC pays a 2.19% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| BCS | WGS | |
|---|---|---|
Market Cap | $93.87B | $2.44B |
Sector | Financials | Technology |
52-Week High | $28.56 | $167.51 |
52-Week Low | $19.36 | $34.51 |
Dividend Yield | 2.19% | — |
Enterprise Value | — | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barclays PLC (BCS) trades at $27.98, up 0.18% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals, including a P/E of 10.68, P/B of 0.88, and net income margin of 25.51%, with Q2 2026 EPS beating estimates at $0.90. Recent news highlights a 17% profit jump in H1 2026 but also a securities class action investigation, creating mixed sentiment.
The outlook is cautiously optimistic, supported by earnings beats and a 68% analyst buy rating, but risks include cost pressures, legal scrutiny, and market volatility. Upside potential hinges on sustained profit growth and efficient cost management amid economic uncertainties.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
